Kingworld Medicines Group Limited (HKG:1110)

Market Cap	283.01M +20.8%
Revenue (ttm)	1.02B -13.5%
Net Income	12.55M -72.9%
EPS	0.02 -73.4%
Shares Out	589.60M
PE Ratio	22.47
Forward PE	n/a
Dividend	0.03 (6.34%)
Ex-Dividend Date	Jun 5, 2025

Volume	484,000
Average Volume	877,000
Open	0.4850
Previous Close	0.4800
Day's Range	0.4750 - 0.4850
52-Week Range	0.4250 - 0.6500
Beta	0.99
RSI	39.94
Earnings Date	Mar 31, 2026

About Kingworld Medicines Group

Kingworld Medicines Group Limited, an investment holding company, primarily engages in the distribution and sale of branded imported pharmaceutical and healthcare products. The company offers products for relieving cough, alleviating phlegm, soothing asthma, enhancing respiratory system, aiding digestion, promoting intestinal health, activating blood circulation, relieving pain, combating flu, and other categories under the Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, Kingworld Imada Red Flower Oil, Culturelle probiotics product series brands...

• Industry: Pharmaceutical Retailers
• Sector: Healthcare
• Founded: 1996
• Employees: 759
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1110

Financial Performance

In 2025, Kingworld Medicines Group's revenue was 917.34 million, a decrease of -13.55% compared to the previous year's 1.06 billion. Earnings were 11.28 million, a decrease of -72.85%.

Financial numbers in CNY